Coinbase CEO Brian Armstrong Raises $130M to Reverse Aging with NewLimit

Coinbase CEO Brian Armstrong is making waves outside the crypto world. His biotech venture NewLimit, aiming to reverse human aging, has raised $130 million in a Series B round that values the company at $810 million.

NewLimit is pioneering epigenetic reprogramming to restore youthful function in aging cells. Their initial breakthroughs include three prototype therapies targeting liver cells, showing improved fat and alcohol metabolism in lab tests.

The funding round was led by Kleiner Perkins with participation from Founders Fund, Elad Gil, Patrick Collison, and Garry Tan – some of Silicon Valley’s top-tier investors.

While human trials are still years away, Armstrong is also pushing U.S. lawmakers to pass the GENIUS Act, a regulatory framework for stablecoins. The bill proposes federal licensing, reserve requirements, and a dual oversight model to manage the rapidly expanding stablecoin sector.

Armstrong is betting on the future—from life extension to crypto regulation, he’s building on every frontier at once.